Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091222840> ?p ?o ?g. }
- W2091222840 endingPage "175" @default.
- W2091222840 startingPage "161" @default.
- W2091222840 abstract "Bevacizumab is the first antiangiogenic agent to have demonstrated benefit as first-line and maintenance therapy in epithelial ovarian cancer (EOC), with the Gynecologic Oncology Group 218 and ICON 7 phase III trials revealing significantly prolonged progression-free survival (PFS) for carboplatin/paclitaxel plus bevacizumab followed by bevacizumab maintenance versus carboplatin/paclitaxel alone. Results are forthcoming from several phase III maintenance trials of investigational antiangiogenic agents, each evaluating PFS as the primary endpoint: AGO-OVAR12/LUME-Ovar1 (nintedanib [BIBF 1120]), AGO-OVAR16 (pazopanib), and TRINOVA-1, -2, and -3 (AMG 386). Here we review available data and ongoing clinical trials of investigational antiangiogenic agents as maintenance therapy for EOC. Current controversies, including uncertainties regarding the (1) most appropriate clinical trial endpoints, (2) optimal dosing, duration, and timing of therapy (e.g., with first-line chemotherapy and/or as maintenance monotherapy), and (3) feasibility, tolerability, and cost of adding these agents to platinum/taxane regimens are also highlighted." @default.
- W2091222840 created "2016-06-24" @default.
- W2091222840 creator A5014611244 @default.
- W2091222840 creator A5025133222 @default.
- W2091222840 creator A5068479857 @default.
- W2091222840 creator A5080528785 @default.
- W2091222840 creator A5086651467 @default.
- W2091222840 date "2013-05-01" @default.
- W2091222840 modified "2023-10-14" @default.
- W2091222840 title "Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer" @default.
- W2091222840 cites W1606254941 @default.
- W2091222840 cites W1967830128 @default.
- W2091222840 cites W1970079579 @default.
- W2091222840 cites W1973183162 @default.
- W2091222840 cites W1973221118 @default.
- W2091222840 cites W1977999028 @default.
- W2091222840 cites W1980179446 @default.
- W2091222840 cites W1989675054 @default.
- W2091222840 cites W1990474270 @default.
- W2091222840 cites W1994855668 @default.
- W2091222840 cites W1997761243 @default.
- W2091222840 cites W2007194438 @default.
- W2091222840 cites W2013288089 @default.
- W2091222840 cites W2014634159 @default.
- W2091222840 cites W2014996434 @default.
- W2091222840 cites W2015522187 @default.
- W2091222840 cites W2017322644 @default.
- W2091222840 cites W2017414151 @default.
- W2091222840 cites W2018929154 @default.
- W2091222840 cites W2023075445 @default.
- W2091222840 cites W2025322581 @default.
- W2091222840 cites W2026697154 @default.
- W2091222840 cites W2041766813 @default.
- W2091222840 cites W2042884540 @default.
- W2091222840 cites W2043588093 @default.
- W2091222840 cites W2052851874 @default.
- W2091222840 cites W2053438624 @default.
- W2091222840 cites W2060097114 @default.
- W2091222840 cites W2066508006 @default.
- W2091222840 cites W2067434109 @default.
- W2091222840 cites W2079537409 @default.
- W2091222840 cites W2081263829 @default.
- W2091222840 cites W2088408857 @default.
- W2091222840 cites W2089756110 @default.
- W2091222840 cites W2093767005 @default.
- W2091222840 cites W2096521047 @default.
- W2091222840 cites W2099022883 @default.
- W2091222840 cites W2103194390 @default.
- W2091222840 cites W2105651363 @default.
- W2091222840 cites W2108923852 @default.
- W2091222840 cites W2109400578 @default.
- W2091222840 cites W2110567194 @default.
- W2091222840 cites W2112940666 @default.
- W2091222840 cites W2113122060 @default.
- W2091222840 cites W2115188495 @default.
- W2091222840 cites W2115310891 @default.
- W2091222840 cites W2120022879 @default.
- W2091222840 cites W2122927195 @default.
- W2091222840 cites W2125857654 @default.
- W2091222840 cites W2128178813 @default.
- W2091222840 cites W2131393213 @default.
- W2091222840 cites W2135947389 @default.
- W2091222840 cites W2138128030 @default.
- W2091222840 cites W2140765540 @default.
- W2091222840 cites W2142610314 @default.
- W2091222840 cites W2142950083 @default.
- W2091222840 cites W2147535764 @default.
- W2091222840 cites W2148326226 @default.
- W2091222840 cites W2154056804 @default.
- W2091222840 cites W2157920585 @default.
- W2091222840 cites W2158219353 @default.
- W2091222840 cites W2160817022 @default.
- W2091222840 cites W2163012374 @default.
- W2091222840 cites W2164168201 @default.
- W2091222840 cites W2201835601 @default.
- W2091222840 cites W2220117191 @default.
- W2091222840 cites W2240422597 @default.
- W2091222840 cites W2280859180 @default.
- W2091222840 cites W2318409487 @default.
- W2091222840 cites W2591120038 @default.
- W2091222840 cites W4249741185 @default.
- W2091222840 cites W4252502442 @default.
- W2091222840 cites W4253705647 @default.
- W2091222840 doi "https://doi.org/10.1016/j.critrevonc.2012.09.012" @default.
- W2091222840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23137764" @default.
- W2091222840 hasPublicationYear "2013" @default.
- W2091222840 type Work @default.
- W2091222840 sameAs 2091222840 @default.
- W2091222840 citedByCount "38" @default.
- W2091222840 countsByYear W20912228402013 @default.
- W2091222840 countsByYear W20912228402014 @default.
- W2091222840 countsByYear W20912228402015 @default.
- W2091222840 countsByYear W20912228402016 @default.
- W2091222840 countsByYear W20912228402017 @default.
- W2091222840 countsByYear W20912228402018 @default.
- W2091222840 countsByYear W20912228402019 @default.
- W2091222840 countsByYear W20912228402020 @default.
- W2091222840 countsByYear W20912228402021 @default.